IL1B and neoplasm: To investigate the role of BRB on cancer cells, Yao et al. showed that the treatment of MDA-MB-231, a triple-negative breast cancer cell line, with BRB results in a significant decrease in the release of pro-inflammatory cytokines such as IL-1α, IL-1β, IL-6, and TNF-α, which are usually involved in tumor proliferation, progression, and metastasis [54].